Applied Health Economics & Outcomes Research (AHEOR) is an academic discipline that establishes the efficacy of a product, service, or treatment; compares its effectiveness to other interventions; and considers its incremental cost efficiency to determine optimal clinical application and overall economic value.

The Master's of Science (MS) builds upon the foundation concepts presented in the Graduate Certificate and focuses on the advanced application of concepts necessary for the modern practice of AHEOR in research and industry settings. This option contains ten online courses and a capstone project, which is specifically designed to enhance the student’s career trajectory. This option can be completed in two years.

Learn more about the program here.

Follow

Submissions from 2024

An Evaluation of the Components and Validity of the Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Philip F. Davis, MBA

Machine Megaphone, Human Voice: How Implementation of Artificial Intelligence and Machine Learning Can Positively Influence Clinical Decision Making by Analyzing Patient Reported Outcomes, Alex Litvintchouk, PharmD, MMS

Launch Readiness Evidence Generation Plan for 177Lu-PNT2002, Jennifer Nguyen, PharmD

Evaluating the Cost-effectiveness of Docetaxel, Carboplatin, and Trastuzumab versus No Adjuvant Therapy with Trastuzumab in Early HER2+ Breast Cancer Treatment, Benson Ninan

Value Proposition Development and HEOR Strategy for Belzutifan in Renal Cell Carcinoma, Olivia Reily

Baricitinib in the Setting of Second-Line Therapy for Rheumatoid Arthritis: A US-Based Budget Impact Model from a Commercial Healthcare Payer Perspective, Zachary Valenzuela

Submissions from 2023

Real-World Evidence is Needed to Complement Clinical Trial Data for the Development of a Product’s Proposition: A Case Study on Real-World Evidence on Pembrolizumab Plus Pemetrexed and Platinum for Advanced NSCLC, KayOnda Bayo

Utility of Medicaid Expansion of Health Outcomes in Female Breast Cancer Patients: Scoping Review, Ife Bilicke

An Analysis on Prevalence, Success, and Implication of Patient Reported Outcomes in Current and Past Clinical Trials, Megan Campbell

The Clinical and Economic Value of Temporary Transvenous Diaphragm Pacing Systems for Mechanically Ventilated Patients in the U.S. Healthcare System, Manuel Dance

Paricalcitol vs Cinacalcet in the Treatment of Chronic Kidney Disease in Patients with Secondary Hyperthyroidism: A Markov Cost-Effectiveness Model, Justin Nabozny

File

A Scoping Review of Microwave Ablation Versus Partial Nephrectomy for Treatment of Renal Cell Carcinoma, Benjamin Odumah

PDF

Cost-Effectiveness Analysis of Canine Heartworm Preventive Products, Emi K. Saito, VMD, MSPH, MBA, DACVPM

Above-Brand Strategic Evidence Plan to Get Regulatory Approval for Subcutaneous PD-1 Ligand Inhibitors for the Treatment of HR-NMBIC, Saif Shaman

Health Technology Assessment Decision-Making Regarding Combination Therapy to Treat Advanced Hepatocellular Carcinoma: Comparison of Appraisals in Canada and the United Kingdom, Marybeth Tran, PharmD

Budget Impact Analysis of Tirbanibulin Field Therapy for Actinic Keratosis in Adult Patients, Cornelius Wagner, PharmD, RPh

Value Proposition Development and HEOR Strategy for Abiraterone in Prostate Cancer, Amy Yang, PharmD

Submissions from 2022

Cost Analysis Of School Vision Screening Programs: Children Eye Health Initiative Of Krishna District, South India, Asha Latha Mettla

Budget Impact Analysis of Long-Acting Reversible Contraceptives for Prevention of Pregnancy in US Females of Childbearing Age, Derek Swiger, PharmD

Submissions from 2021

Machine Learning Optimization of ICU Care: A Cost-Effectiveness Model, Mario V. Fusaro, MD

Medical Affairs and Successful Medical Device Strategies: Best Practices for Return on Intelligence (ROI), Haytham Gareer, MD, MBA, PhD

The use of a Markov Cost-Effectiveness Analysis and a PRO Instrument to Inform and Evaluate the Clinical and Economic Value of Drug Interventions, Laetitia A. N'Dri, PharmD, RPh

Budget Impact Analysis of Semaglutide for Weight-loss Management in Overweight and Obese U.S. Adults, Tobin Sebastian, PharmD

Evidence For Pomalidomide In 2nd Line Treatment Of Relapse Refractory Multiple Myeloma, Ryan Thomas, PharmD

Submissions from 2020

Phyllodes Tumor of the Breast: Association Between Age, Surgical Treatment and Survival, Alberto Batista, PharmD, AHEOR Student and Karen Walsh, MS, MBA

5- and 10-Year Cost-Effectiveness of Bariatric Surgery in Super Obese, Middle-Aged Patients: A United States Perspective, R. Ditto and I. Kim

The Prevalence of Microalbuminuria in Adolescents with Obesity in United States Using the National Health and Nutrition Examination Survey (NHANES) Data 2011-2016TA 2011-2016, Fournier Janine, PharmD, AHEOR Student and Karen Walsh, MS, MBA

Clinical and Economic Value of Implementing a Geriatric Hip Fracture Program in Hospitals in the United States, A. M. Menzie and V. Maio

The Impact of Biologic Therapy on Health-related Quality of Life in Pediatric Psoriasis, Lauren Siegel, MS, AHEOR Student and Alex Niyazov, PharmD, MPH

Systematic literature review on the effect of antidepressants on sleep impairment in major depressive disorder, Jennifer Voelker, MS AHEOR Student and J McAna

Submissions from 2018

A Systematic Literature Review and Economic Evaluation with a Meta-Analysis of Randomized Control Trials Focusing on Symptom Reduction in Adults Ages 18 and Older Treated by Either Esomeprazole, Omeprazole, Lansoprazole, Rabeprazole, or Pantroprazole for Diagnosed Reflux Disease in North America and Europe, Kajan Gnanasakthy

Submissions from 2017

Identification of Cognitively Impaired Patients At Risk For Development of Alzheimer's Disease: An Analysis of US Medicare Claims Data, Michele Potashman, PhD

Submissions from 2016

The Clinical and Economic Impact of Tyrosine Kinase Inhibitor Non-adherence in CML Patients within a US Integrated Healthcare System, Amir Aminimanizani, Pharm D

The Economic Value of Biosimilars, Samantha Simpson

Submissions from 2015

The Economic Impact of a Pharmacy-Based Intervention among Patients with Schizophrenia, Tony Amos

Comparative Effectiveness of SGLT2 Inhibitors vs. Sitagliptin Add-on Therapy to Metformin inType-2 Diabetes, Chris Sevald

Submissions from 2014

PDF

Direct Comparison of Apremilast and Best Supportive Care Using a Discrete Event Simulation, Zoe Clancy, PharmD

Health Technology Assessment (HTA) of Roux-en-Y Gastric Bypass compared to Sleeve Gastrectomy in obese type 2 diabetic adults, Sepehr Farahbakhshian, MS